FDA Approval: Telisotuzumab Vedotin and MET-Positive NSCLC
In this episode, we will discuss the FDA approval of telisotuzumab vedotin, an antibody drug conjugate, for NSCLC with high c-MET expression. To help review the data and offer perspective on this new agent, I am joined by two expert thoracic oncologists. I want to welcome Dr. Mor Moskovitz, Head of the Thoracic Medical Oncology Service at Davidoff Cancer Center at the Rabin Medical Center in Petah Tikva, Israel.
--------
33:15
--------
33:15
LCC in Korean: Lung Cancer Updates & Future Directions
LCC in Korean: Lung Cancer Updates & Future Directions by IASLC
--------
33:41
--------
33:41
Global Advances and Persistent Disparities in Lung Cancer Treatment
Global Advances and Persistent Disparities in Lung Cancer Treatment by IASLC
Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
Lung Cancer considered is funded in part by AstraZeneca, Daiichi Sankyo, Inc., and Takeda
Brasil